Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Key Highlights
- ➤Paper accepted, introducing QRX003’s mechanism and pediatric compassionate-use case
- ➤Pediatric case achieved fully healed skin and complete itch elimination
- ➤Phase 2/3 interim: 4 of 6 patients achieved primary endpoint at 12 weeks
- ➤June update: 4 of 6 pediatric patients classified Improved or Significantly Improved
Expert Statements
Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
“Acceptance of this paper by a peer-reviewed dermatology journal is important recognition of the scientific rationale behind QRX003 and its potential in Netherton Syndrome. We are grateful to Professor Irvine for documenting his clinical experience treating a pediatric patient with QRX003”
Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals
“Because Netherton Syndrome is a genetic disease, the experience of pediatric patients is especially important as we advance QRX003. This case report adds to the growing body of clinical evidence supporting the program, including the positive interim results from our ongoing Phase 2/3 study.”
* Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome * Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of Dermatology and Therapy.
The peer-reviewed paper introduces QRX003, the Company’s investigational topical serine protease inhibitor lotion, and describes its mechanism of action in Netherton Syndrome. It also presents a case report from Professor Alan Irvine, consultant dermatologist at Children’s Health Ireland and professor of dermatology at Trinity College Dublin, describing his positive clinical experience treating a pediatric patient with QRX003 under Quoin’s Pediatric Compassionate Use Program. The paper describes the impact that QRX003 has had on the patient leading to fully healed skin, complete elimination of pruritus (itch) which has led to zero nightly sleep disturbances as a result and significant reduction in need for all previously required medications.
Get started
Create a free account to read the full story.